Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway

Fig. 4

Mechanism of DCZ0805-induced tumor inhibition. a H929 and ARP-1 cells were cultured with 10 μM and 20 μM DCZ0805 for 48 h. Western blot analysis was used to evaluate the protein expression level of NF-κB, p-NF-κB, IκBα, p-IκBα, p-IKKα/β and Actin. b NF-κB transcriptional activity in ARP-1 cells treated with DCZ0805 (10 μM, 48 h), alone or in combination with TNF-α (30 ng/mL). ***P < 0.001 compared to the control group, data represent the mean ± SD from three separate experiments. c Levels of total and phosphorylated NF-κB in ARP-1 cells treated with DCZ0805 (10 μM, 48 h) alone or in combination with TNF-α (30 ng/mL)

Back to article page